# Simplified COVID-19

# Schedules & More

Tuesday, April 25, 2023










# Agenda

- New Schedules by Age Group − Illinois Chapter, American Academy of Pediatrics (ICAAP) and Illinois Vaccinates Against COVID-19 (I-VAC): Daniel Johnson, MD, FAAP
- ▶ Product Expirations and Ordering Chicago Department of Public Health: Kevin Hansen and Illinois Department of Public Health: Karyn Lyons, MS, RN
- ▶ What We Know About Commercialization –Illinois Vaccinates Against COVID-19 (I-VAC): Jennifer Burns, APN
- ▶ Q & A Session Moderated by ICAAP: Caroline Werenskjold, MPH

## **The State of COVID-19**




# Hooray!

A simplified schedule is here...sort of.

Not for children.

## **Products in Use**



### **How We Got Here**



INCORPORATED IN ILLINOIS





## 4.18.23 FDA Amended EUAs

Of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines.

> Moderna Pfizer



4.19.23 ACIP Met

Discussed vaccine data and schedules. No votes.



4.19.23 CDC Endorsed Support

It is all happening.

# **Bivalent Vaccines**

#### CDC presented data that shows:

- Bivalent vaccines are safe.
- Effectiveness: Waning against hospitalization.
- Efficacy for bivalent vaccines among those over 65 years decreased from 64% to 39%.

### AGES 6 **MONTHS TO** <5 YEARS

#### **Additional Considerations**

An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months-64 years, especially for males ages 12-39 years, as data suggests it reduces the small risk of myocarditis and pericarditis associated with these vaccines.

#### UNVACCINATED

dose/injection volume


#### Moderna Bivalent:

(Do NOT dilute before use) Dark Blue Cap (gray label)

#### Pfizer Bivalent:

(dilute before use) Maroon Cap





dose/injection volume


Previously Received **COVID-19 Vaccines** 

#### Moderna Bivalent:

(Do NOT dilute before use) Dark Blue Cap (gray label) Dark Pink Cap (yellow label)

#### Pfizer Bivalent:

(dilute before use) Maroon Cap



# AGES 6 MONTHS TO <5 YEARS - MODERATELY TO SEVERELY IMMUNOCOMPROMISED

For Pfizer, there is no new additional guidance for immunocompromised at this time.

For Moderna for the unvaccinated, give an extra dose as indicated in the chart.

Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.


#### UNVACCINATED

dose/injection volume

#### Moderna Bivalent:

(Do NOT dilute before use)
Dark Blue Cap (gray label)

Pfizer Bivalent: (dilute before use) Maroon Cap



### PREVIOUSLY VACCINATED


dose/injection volume

Previously Received COVID-19 Vaccines

#### Moderna Bivalent:

(Do NOT dilute before use)
Dark Blue Cap (gray label)
Dark Pink Cap (yellow label)

Pfizer Bivalent: (dilute before use) Maroon Cap



Up-to-date

# AGES 5 TO <6 YEARS

#### UNVACCINATED

dose/injection volume

#### Moderna Bivalent:


(Do NOT dilute before use)
Dark Blue Cap (gray label)

#### Pfizer Bivalent:

(dilute before use)
Orange Cap

### PREVIOUSLY VACCINATED

dose/injection volume



#### Moderna Bivalent:

(Do NOT dilute before use)
Dark Blue Cap (gray label)
Dark Pink Cap (yellow label)

#### Pfizer Bivalent:

(dilute before use)
Orange Cap



# AGES 5 TO <6 YEARS IMMUNOCOMPROMISED

#### **Immunocompromised Guidance for Pfizer-BioNTech**

For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer- BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

#### **Immunocompromised Guidance for Moderna**

For individuals with certain kinds of immunocompromise 5 to <6 years of age who have received two 0.25 mL doses (Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent), an additional 0.25 mL dose of Moderna COVID-19 Vaccine, Bivalent (vial with a dark blue cap and a label with a gray border) may be administered at least 1 month following the most recent dose; additional doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

### **AGES 6 TO** <12 YEARS

#### UNVACCINATED

dose/injection volume

#### Moderna Bivalent:

(Do NOT dilute before use) Dark Blue Cap (gray label)

#### Pfizer Bivalent:

(dilute before use) Orange Cap



#### **PREVIOUSLY** VACCINATED

dose/injection volume




**Previously Received** COVID-19 Vaccines

#### Moderna Bivalent:

(Do NOT dilute before use) Dark Blue Cap (gray label) Dark Pink Cap (yellow label)

#### Pfizer Bivalent:

(dilute before use) **Orange Cap** 



# AGES 6 TO <12 YEARS IMMUNOCOMPROMISED

#### **Immunocompromised Guidance for Pfizer-BioNTech**

For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer- BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

#### **Immunocompromised Guidance for Moderna**

For individuals with certain kinds of immunocompromise 6 years and older who have received one 0.25 mL doses (Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent), an additional 0.25 mL dose of Moderna COVID-19 Vaccine, Bivalent (vial with a dark blue cap and a label with a gray border) may be administered at least 1 month following the most recent dose; additional doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

### **AGES 12 YEARS** AND OLDER



dose/injection volume

#### Moderna Bivalent:

(Do NOT dilute before use) Dark Blue Cap (gray label)

#### Pfizer Bivalent:

(Do NOT dilute before use) Gray Cap

#### Moderna **BIVALENT** Up-to-date 50 μg/0.5 mL OR Pfizer BIVALENT Up-to-date 30 μg/0.3 mL

#### **PREVIOUSLY** VACCINATED

dose/injection volume



Previously Received **COVID-19 Vaccines** 

#### Moderna Bivalent:

(Do NOT dilute before use) Dark Blue Cap (gray label)

#### Pfizer Bivalent:

(Do NOT dilute before use) **Gray Cap** 



#### ADDITIONAL DOSES

dose/injection volume



Previously Received **COVID-19 Vaccines** 

#### Moderna Bivalent:

(Do NOT dilute before use) Dark Blue Cap (gray label)

#### Pfizer Bivalent:

(Do NOT dilute before use) **Gray Cap** 

#### **65 YEARS AND OLDER**

People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.







Up-to-date

#### **AGES 12 YEARS AND OLDER**

#### **Immunocompromised Guidance for Pfizer-BioNTech**

For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer- BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

#### **Immunocompromised Guidance for Moderna**

For individuals with certain kinds of immunocompromise 6 years and older who have received one 0.25 mL doses (Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent), an additional 0.25 mL dose of Moderna COVID-19 Vaccine, Bivalent (vial with a dark blue cap and a label with a gray border) may be administered at least 1 month following the most recent dose; additional doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

### **Monovalent mRNA Vaccines**

- No longer authorized.
- Should be immediately removed from inventory.
  - You should waste them in I-CARE and mark them out of stock.
- All monovalent Moderna and Pfizer-BioNTech mRNA vaccines should be disposed of in medical waste containers.
  - Medical waste disposal requirements may vary by jurisdiction.

# If a deauthorized vaccine is inadvertently administered?

- Review Interim Clinical Considerations for Use of COVID-19 Vaccines.
- ▶ Report vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS).

What about people who received Novavax or Janssen vaccines as their primary series?

- No new information provided.
- People ages 18 years and older who completed primary vaccination and have **not** received any previous booster dose(s) (including any previous monovalent or bivalent mRNA booster dose[s]) may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

### What if someone just had COVID-19?

No new update based on infection history.

What about pregnant people?

▷ Eligible for *one* bivalent booster.

#### **STORAGE & HANDLING**

#### **MODERNA STORAGE & HANDLING INFORMATION**



AGE INDICATIONS AND FORMULATION	6 months through 5 years (Bivalent)	6 months and older (Bivalent)	
VIAL CAP COLOR	Dark Pink	Dark Blue	
VIAL LABEL BORDER COLOR	Yellow Gray		
PREPARATION	Do Not Dilute Do Not Dilute		
DOSE VOLUME/DOSE	6 months to 5 years old: 0.25     0.2 mL/10 mcg     6 to 11 years old: 0.25 mL/25     12 years and older: 0.5 mL/5		
DOSES PER VIAL	2 doses	Varies by age	
ULT FREEZER (-90°C TO -60°C)	DO NOT STORE		
FREEZER (-50°C TO -15°C) <sup>a</sup>	Until expiration		
REFRIGERATOR (2°C TO 8°C)	30 days		
ROOM TEMPERATURE (8°C TO 25°C) including any thaw time	24 hours		
AFTER FIRST PUNCTURE (2°C TO 25°C) <sup>b</sup>	Discard after 8 hours	Discard after 12 hours	

- Regardless of storage condition, vaccines should not be used after the expiration date.
- b After a vial is punctured 20 times it should be discarded even if the 12-hour time limit has not been met.

#### **STORAGE & HANDLING**

#### **PFIZER-BIONTECH STORAGE & HANDLING INFORMATION**



AGE INDICATIONS	6 months through 4 years	5 years through 11 years	12 years and older	
FORMULATION	Bivalent	Bivalent	Bivalent	
VIAL CAP COLOR/LABEL WITH COLOR BORDER	Maroon/ Bivalent label	Orange/ Bivalent label	Gray/ Bivalent label	
PREPARATION	Dilute Before Use	Dilute Before Use	Do Not Dilute	
AMOUNT OF DILUENT NEEDED PER VIAL <sup>a</sup>	2.2 mL	1.3 mL		
DOSE VOLUME/DOSE	0.2mL/3mcg	0.2 mL/10 mcg	0.3 mL/30 mcg	
DOSES PER VIAL	10 doses (after dilution)	10 doses (after dilution)	6 doses or 1 dose	
ULT FREEZER (-90°C TO -60°C) <sup>b</sup>	18 months			
FREEZER (-25°C TO -15°C)	DO NOT STORE			
REFRIGERATOR (2°C TO 8°C)	10 weeks			
ROOM TEMPERATURE (8°C TO 25°C) including any thaw time	12 hours prior to first puncture			
AFTER FIRST PUNCTURE (2°C TO 25°C)	Discard after 12 hours			

- Diluent: Sterile 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.
- b Regardless of storage condition, vaccines should not be used after 12 months from the date of manufacture printed on the vial and cartons.

#### **STORAGE & HANDLING**



#### JANSSEN & NOVAVAX STORAGE & HANDLING INFORMATION

	<b>JANSSEN</b> (Johnson & Johnson)	NOVAVAX	
AGE INDICATIONS	18 years and older	12 years and older	
FORMULATION	Primary Series and Booster Dose	Primary Series	
VIAL CAP COLOR/ LABEL WITH COLOR BORDER	Blue Cap, White Label	Royal Blue Cap	
PREPARATION	Do Not Dilute	Do Not Dilute	
DOSE VOLUME/DOSE	5 X10 <sup>10</sup> viral particles	0.5mL / 5mcg rS and 50mcg of Matrix M adjuvant	
DOSES PER VIAL	5 primary doses or booster doses	10 or 5	
ULT FREEZER (-90°C TO -60°C)	N/A	N/A	
FREEZER (-25°C TO -15°C)	N/A	N/A	
REFRIGERATOR (2°C TO 8°C) <sup>a</sup>	Up to 11 months	Until expiration date	
ROOM TEMPERATURE (8°C TO 25°C) including any thaw time	12 hours prior to first puncture	N/A	
AFTER FIRST PUNCTURE (2°C TO 25°C)	Administer within 6 hours if refrigerated or within 2 at room temperature	12 hours	

Regardless of storage condition, vaccines should not be used after the expiration date.

## **Ordering Quantities**

# Packing will continue to say "booster only" on some products

	Pfizer			Moderna		
Formulation	6 mos – 4 years Bivalent (maroon cap)	5 – 11 years Bivalent (orange cap)	12+ years Bivalent (gray cap)	12+ years Bivalent Single-Dose Vials (gray cap)	6 mos – 5 years Bivalent	6+ months Bivalent
# vials per tray	10	10	10	10	10	10
# doses per tray	100	100	60	-	20	50
Minimum order quantity	100 doses	100 doses	180 doses	50 doses	20 doses	100 doses
Delivery time	~1 week			~1 Week for Av	ailable Products	

### Janssen & Novavax

- **▶ 10 dose Novavax vials expire April 30, 2023**

	Janssen	Novavax
Formulation	18+	12+
# vials per tray	10	10
# doses per tray	100	50
Minimum order quantity	100 doses 100 doses (2 trays	
Delivery time	~1 week	

## End of Public Health Emergency (PHE) - Federal

- ► The federal PHE will end May 11, 2023.
- COVID-19 vaccines will still be available EUAs will not be impacted.
- ▷ Insurance companies will no longer be required to cover the cost of COVID-19 tests.
- ► HHS will no longer be able to require reporting of COVID-19 test results.
- ➤ The end of the PHE is **not** tied to the commercialization of COVID-19 vaccines.

# **End COVID-19 Disaster Proclamation - Illinois**

- ▶ Will end May 11, 2023.
- ▶ The proclamation allowed for...
  - > Federal reimbursement for state response costs.
  - Use of State Disaster Relief Fund, covering direct state costs and reimbursements to Illinois National Guard and mutual aid groups.
  - Use of the state's mutual aid network, groups of public safety response professionals (health care providers and management professionals, law enforcement officers, fire fighters, emergency medical technicians, disaster response professionals) that are available to deploy to areas of shortage.
  - ▶ The activation of Illinois National Guard reservists, some of whom were doctors and nurses and served on the front lines of the pandemic response.
  - Additional executive actions as needed to protect public health and safety.

### **Future Vaccinators**

► HHS announcement last week on <u>PREP Act and Pharmacy</u>
Administration of Vaccines

# Commercialization – Coming Fall 2023?

- The transition from direct government purchase to purchase by public and private payers.
- - Will be covered by Vaccines for Children (VFC) program.
- Upfront costs for providers who purchase COVID-19 vaccines how much is unknown.

### What is Next

#### Illinois Chapter

INCORPORATED IN ILLINOIS





#### **June 2023**

The FDA meets to discuss the fall vaccine plans and the vaccine variant formula.



June 21-22 ACIP Meetings



# Messaging

- ▶ Those under 5 needs to get a primary series.
- Everyone who is not vaccinated should get vaccinated.
- Everyone should get a bivalent dose.
- ▶ Everyone who is immunocompromised should consider getting a second bivalent dose.
  - Work with your provider.
- Acceptable to give a second bivalent to anyone 65+ (provider determination).
- ▶ We anticipate a future recommendation for an annual COVID-19 vaccine.

# Q & A

Please use the Q & A box only.

### **Contact Information & Resources**

#### **IDPH**

- dph.vaccines@illinois.gov
- ▶ I-CARE: <a href="mailto:dph.immunizations@illinois.gov">dph.immunizations@illinois.gov</a>
- HL7: <u>DPH.HL7ICARE@illinois.gov</u>

#### **CDPH**

- ChicagoVFC@cityofchicago.org
- Kevin Hansen: <u>Kevin.Hansen@cityofchicago.org</u>
- COVID19vaccine@cityofchicago.org
- chicagohan.org/vfc
- chicagohan.org/covid-19-vaccine/provider

#### ICAAP/I-VAC

- Illinoisaap.org
- ▶ Illinois Vaccinates Against COVID-19
- Facts@ilvaccinates.com

#### **Additional Resources:**

- Updates to Interim Clinical Considerations for Use of COVID-19 Vaccines
- ► HHS COVID-19 Vaccine Planning Guide
   Spring/Summer 2023
- Presentation: Updates to COVID-19 vaccine policy:
   Considerations for Future Planning (ACIP)
- Moderna COVID-19 Vaccines (FDA)
- Pfizer COVID-19 Vaccines (FDA)
- Fact Sheet: HHS Announces Intent to Amend the Declaration Under the PREP Act for Medical Countermeasures Against COVID-19

## **Upcoming Events**

- ► Illinois Vaccinates Against COVID-19

   (I-VAC) Learning Collaborative –

   Pediatric Populations
- Preparing for Summer Vacations –Travel Vaccinations
  - ▶ Tuesday May 16th, 12:00PM 1:00PM

- **▷ I-VAC Vaccine Bootcamp In Person** 
  - Friday June 16th, 8:30AM 2:00PM
- ▶ Back to School, Back to VaccineBasics National ImmunizationAwareness Month
  - ▶ Tuesday June 20th, 12:00PM − 1:00PM





### **Manufacturer Office Hours**

#### **Novavax Office Hours**

- ▶ Use this <u>link</u> to register
  - ▶ Tuesday, April 25 @ 2:00PM CDT
  - Wednesday, May 3 @ 1:00PM CDT

#### **Moderna Office Hours**

- Use this <u>link</u> to register −office hours available through Tuesday April 25<sup>th</sup> − Friday May 5<sup>th</sup>:
  - Tuesday, April 25 @ 1:00PM CDT
  - ▶ Wednesday, April 26 @ 11:00AM CDT & 1:00PM CDT

#### **Pfizer Office Hours**

- ▶ Use this <u>link</u> to register office hours available through Tuesday April 25<sup>th</sup> Thursday May 11<sup>th</sup>:
  - ▶ Tuesday, April 25 @ 2:00PM CDT
  - Wednesday, April 26 @ 11:00AM CDT